NASDAQ · ELAN
Healthcare · Drug Manufacturers - Specialty & Generic
$24.11
Down-$0.38 (-1.55%)
Updated Aug 31, 2026, 12:53 PM
SID Score
5.5/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ELAN closed at $24.11 after 20 trading sessions, down 6.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $24.45 | $24.755 | $23.99 | $24.11 | 4.17M |
| Aug 27, 2026 | $24.91 | $25.04 | $24.42 | $24.49 | 4.09M |
| Aug 26, 2026 | $25.02 | $25.19 | $24.84 | $25.08 | 4.15M |
| Aug 25, 2026 | $24.60 | $25.405 | $24.46 | $25.09 | 5.31M |
| Aug 24, 2026 | $24.11 | $24.54 | $24.03 | $24.42 | 3.95M |
| Aug 21, 2026 | $23.91 | $24.15 | $23.685 | $23.97 | 4.76M |
| Aug 20, 2026 | $24.21 | $24.37 | $23.38 | $23.56 | 4.94M |
| Aug 19, 2026 | $24.08 | $24.57 | $24.00 | $24.50 | 3.97M |
| Aug 18, 2026 | $23.59 | $23.85 | $23.44 | $23.64 | 5.08M |
| Aug 17, 2026 | $23.44 | $23.81 | $23.08 | $23.61 | 7.15M |
| Aug 14, 2026 | $22.75 | $23.69 | $22.67 | $23.67 | 6.5M |
| Aug 13, 2026 | $22.31 | $22.6796 | $22.17 | $22.51 | 5.57M |
| Aug 12, 2026 | $22.40 | $22.495 | $21.75 | $22.13 | 9.72M |
| Aug 11, 2026 | $23.00 | $23.07 | $22.55 | $22.73 | 7.55M |
| Aug 10, 2026 | $22.12 | $22.81 | $21.32 | $22.28 | 22.49M |
| Aug 7, 2026 | $24.38 | $24.41 | $22.02 | $22.12 | 22.08M |
| Aug 6, 2026 | $25.345 | $25.345 | $23.60 | $24.20 | 17.21M |
| Aug 5, 2026 | $27.08 | $27.98 | $25.10 | $26.22 | 13.87M |
| Aug 4, 2026 | $25.74 | $25.98 | $25.295 | $25.60 | 9.07M |
| Aug 3, 2026 | $26.29 | $26.45 | $25.40 | $25.72 | 5.39M |
The latest Smart Investors Daily articles mentioning ELAN.
ELAN research
Company profile and research snapshot.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Keybanc | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
| Jul 22, 2026 | Morgan Stanley | Equal-Weight | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal
SeekingAlpha · Aug 19, 2026
Elanco Animal Health's Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth. Read why ELAN stock is a Buy.
Yahoo · Aug 19, 2026
Insider buys into strength as the Elanco stock price has outperformed the S&P 500 over the last 12 months.
Benzinga · Aug 19, 2026
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELAN.
